CD55 and neoplasm: Notably, there was no statistical difference in the tumour growth inhibition between the PBS and Dox group, implying that the dosage of Dox (1.2 mg/kg) alone almost did not suppress the tumour growth, but can greatly enhance the antitumour effects of CD55‐TMn in vivo.